
|Videos|April 26, 2019
CLL Case Review: IgHV-Unmutated Therapy Options
CLL Case Review: IgHV-Unmutated Therapy Options
Advertisement
Case:A 74-Year-Old Male WithIgVH-Unmutated CLL
- A 74-year-old male presented to PCP with complaints of extreme fatigue, weakness, and weight loss of ~15lbs over the last 3 months.
- PMH: Mild hypertension managed by statin
- PE: BP 135/85, enlarged lymph nodes (~6cm), palpable spleen approx. 7cm below costal margin
- Laboratory findings:
- WBC; 100 X 109/L
- Lymphocytes; 82 X 109/L
- Hb; 15.1 g/dL
- Platelets; 125 X 109/L
- ANC; 1,800/mm3
- LDH 250 u/L
- β2M, 4.3 mg/L
- FISH; normal
- Molecular analysis;IgVH-,TP53wild-type
- ECOG PS 1
- Rai Stage II
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5









































